LBP-002 - Treatment efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12- and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study
| Autor: | Hirschfield, G., Boudes, P., Bowlus, C., Gitlin, N., Michael, G., Harrison, S., Gordon, S.C., Aspinall, R., Doerffel, Y., Kremer, A.E., Sheridan, D., Bacon, B., Berg, C., Borg, B., Hassanein, T., Odin, J., Shiffman, M., Thuluvath, P.J., Thorburn, D., Bernstein, D., Buggisch, P., Corless, L., Levy, C., Mayo, M.J., Swain, M.G., Vierling, J., Wörns, M.-A., Steinberg, A.(S.), Bergheanu, S., Choi, Y.-J., Varga, M., Martin, R., Mcwherter, C., Jones, D. |
|---|---|
| Zdroj: | In Journal of Hepatology April 2018 68 Supplement 1:S105-S106 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect